Owing to the discovery of druggable genetic alterations and mutations such as EGFR, ROS1, ALK, RET, FGFR1, MET Exon 14 and NTRK, the management of NSCLC has been altered dramatically. Here, MET is linked to non-small cell lung carcinoma.